Search

Search Constraints

You searched for: Author/Creator Charles, Julie

Search Results

1. An innovative plasmacytoid dendritic cell line-based cancer vaccine primes and expands antitumor T-cells in melanoma patients in a first-in-human trial. (1st January 2020)

2. BDCA1+ cDC2s, BDCA2+ pDCs and BDCA3+ cDC1s reveal distinct pathophysiologic features and impact on clinical outcomes in melanoma patients. Issue 11 (24th November 2020)

3. Co-delivery of the NKT agonist α-galactosylceramide and tumor antigens to cross-priming dendritic cells breaks tolerance to self-antigens and promotes antitumor responses. (2nd September 2017)

5. Diversification of circulating and tumor‐infiltrating plasmacytoid DCs towards the P3 (CD80+ PDL1−)‐pDC subset negatively correlated with clinical outcomes in melanoma patients. Issue 5 (3rd May 2022)

6. Dysfunctional BTN3A together with deregulated immune checkpoints and type I/II IFN dictate defective interplay between pDCs and γδ T cells in melanoma patients, which impacts clinical outcomes. Issue 11 (9th November 2021)